Global Information
회사소개 | 문의

세계의 마이크로바이옴 치료약 및 진단약 시장 분석과 예측(-2023년)

Global Microbiome Therapeutics & Diagnostics Market Analysis & Forecast to 2023

리서치사 Kelly Scientific Publications
발행일 2018년 09월 상품 코드 696428
페이지 정보 영문 165 Pages
가격
US $ 4,900 ₩ 5,625,200 PDF by E-mail (Single User License)
US $ 9,800 ₩ 11,250,400 PDF by Email - (Mid Level License) (up to 10 people)
US $ 14,700 ₩ 16,875,600 PDF by E-mail (Enterprise Wide License)


세계의 마이크로바이옴 치료약 및 진단약 시장 분석과 예측(-2023년) Global Microbiome Therapeutics & Diagnostics Market Analysis & Forecast to 2023
발행일 : 2018년 09월 페이지 정보 : 영문 165 Pages

한글목차

세계의 마이크로바이옴 치료약 및 진단약 시장은 예측기간 중 19.03%의 연평균 성장률(CAGR)로 성장하여 2018년 11억 3,000만 달러에서 2023년에는 27억 달러 이상의 규모로 확대될 전망입니다.

세계의 마이크로바이옴 치료약 및 진단약(Microbiome Therapeutics & Diagnostics) 시장에 대해 조사했으며, 마이크로바이옴의 개요, 치료약 및 진단약 파이프라인 분석, 치료/진단 구분·적응증·지역별 동향, 시장 규모 추정과 예측, 시장에 대한 각종 영향요인 및 시장 기회 분석, 투자·계약 동향, 경쟁 상황, 주요 기업 개요 등의 정보를 전해드립니다.

제1장 주요 요약

제2장 마이크로바이옴 : 개요

  • 마이크로바이옴 : 개요
  • 건강 및 질환과 인간 마이크로바이옴
    • 비만
    • 장내 세균총대사
    • 2형 당뇨병
    • 궤양성 대장염 및 크론병
    • 클로스트리듐 디피실 감염증
    • 유당불내성
    • CNS 질환(장-뇌 축)
    • 충치
    • 재발성 세균성 질염 및 요로 감염증
    • 피부 질환
    • 과수산뇨증
    • 요소회로이상증
    • 셀리악병
    • 비알코올성 지방간염(NASH)
    • 간성뇌증
  • 마이크로바이옴 치료약 종류
    • 프리바이오틱스
    • 프로바이오틱스
    • 분변이식(FMT : Fecal Microbiota Transplantation)
    • 저분자약
  • 마이크로바이옴 연구의 발전
  • 마이크로바이옴의 지역적 다양성

제3장 치료약 및 진단약 파이프라인 분석

  • 개요
  • 클로스트리듐 디피실
    • SER-109 : Seres Therapeutics
    • SER-262 : Seres Therapeutics
    • RBX2660 : Rebiotix
    • VE303 : Vedanta Biosciences
    • IMM-529 : Immuron
    • MET-2 : NuBiyota
    • CP101 : Finch Therapeutics
    • ABI-M101 : Assembly Biosciences
    • CBM-588 : Osel
    • SYN-004 : Synthetic Biologics
    • SYN-006 : Synthetic Biologics
  • 궤양성 대장염
    • FIN-524 : Finch Therapeutics
    • SER-287 : Seres Therapeutics
    • ABI-M201 : Assembly Biosciences
  • 크론병
    • ABI-M301 : Assembly Biosciences
    • Thetanix : 4D Pharma
  • 염증성 장질환
    • SER-301 : Seres Therapeutics
    • SGM-1019 : Second Genome
    • Blautix : 4D Pharma
    • SG-2-0776 : Second Genome
    • IBD110 : Enterome/AbbVie
  • 종양 면역 관련
    • SER-401 : Seres Therapeutics
    • 대장 용종 및 결장암 검사 : Metabiomics
    • 대장암(CRC) 검사 : Origin Sciences
  • 이식편대숙주병(GVHD)
    • SER-155 : Seres Therapeutics
  • 요로 감염증
    • LACTIN-V : Osel
  • 간질환
    • SGM-1019 : Second Genome
  • 페닐케톤뇨증
    • SYNB1020 : Synlogic
    • SYNB1618 : Synlogic

제4장 시장 분석과 예측

  • 개요
  • 용도
    • 클로스트리듐 디피실 감염증
    • 염증성 장질환
    • 궤양성 대장염
    • 크론병
    • 간질환
    • 면역 종양 관련
    • 페닐케톤뇨증
  • 경쟁 상황
  • 시장 예측
    • 개요
    • 1차 조사, 임상시험 및 파이프라인 동향과 분석
    • 매출 예측
    • 시장 분석과 예측 : 지역별
    • 시장 분석과 예측 : 치료/진단 구분별, 적응증별

제5장 시장 성장 촉진요인, 동향, SWOT 분석

  • 성장 촉진요인과 동향
  • 성장 억제요인과 과제
  • 시장 기회

제6장 투자와 계약

제7장 벤처 캐피털과 마이크로바이옴

제8장 주요 기업 개요

  • 4D Pharma
  • Abbvie
  • Allergan
  • Assembly Biosciences
  • Bristol Myers Squibb
  • C3J Therapeutics
  • Da Volterra
  • Enterome
  • Finch Therapeutics
  • Immuron
  • Matrisys Bioscience
  • Merck
  • Osel
  • Pfizer
  • Quorum Innovations
  • Rebiotix
  • Second Genome
  • Seres Therapeutics
  • Synlogic
  • Synthetic Biologics
  • Takeda
  • Vedanta Biosciences
KSM 18.09.18

영문목차

This report provides a comprehensive overview of the size of the microbiome therapeutic and diagnostic market, segmentation of the market (Gastrointestinal, Metabolic, Cancer, Neurological, Autoimmune, Skin), key players and the potential of therapies that are in clinical trials. Kelly Scientific analysis indicates that the global microbiome therapeutic and diagnostic market is worth $1.13 billion in 2018 and will grow at a CAGR of 19.03% over five years to $2.7 billion in 2023. The majority of the market will be dominated by microbiome based therapeutics, with an estimate of x%, compared to x% in microbiome diagnostics. This report describes the evolution of such a prospective market in eight chapters supported by over 82 tables and figures in 165 pages.

  • An overview of the human microbiome space that includes how the market is sub-divided into therapeutics (prebiotics, probiotics, fecal microbiota transplantation, small molecules) and diagnostics.
  • Global microbiome market, global breakdown, application breakdown and leading market players
  • Detailed account of the microbiome industry market by geography, indication and company profiles
  • Profiles, pipeline products, financial analysis and business strategy of the major companies in this space
  • Focus on current trends, business environment, pipeline products, clinical trials, and future market forecast for microbiome therapeutics and diagnostics
  • Insight into the challenges faced by stakeholders
  • Insight into the biobanking industry globally and its impact on the overall market
  • Description and data for the prevalence of disease types that are addressed by harnessing the human microbiota
  • Financial market forecast through 2023 with CAGR values of all market segments outlined in the objective
  • SWOT analysis of the global market
  • Geographical analysis and challenges within key topographies including North America, Europe, Asia/Pacific, Middle East/Africa, ROW

Table of Contents

Chapter 1: Executive Summary

  • 1.1. Synopsis
  • 1.2. Objective of Report
  • 1.3. Executive Summary
  • 1.4. Key Questions Answered
  • 1.5. Data Sources & Methodology

Chapter 2: Microbiome Overview

  • 2.1. Microbiome Overview
  • 2.2. Human Microbiome in Health and Disease
    • 2.2.1. Cancer
    • 2.2.2. Obesity
    • 2.2.3. Microbiota Metabolism
    • 2.2.3. Type 2 Diabetes Mellitus
    • 2.2.4. Ulcerative Colitis and Crohn's Disease
    • 2.2.5. Clostridium Difficile Infection
    • 2.2.6. Lactose Intolerance
    • 2.2.7. CNS Disorders (gut brain axis)
    • 2.2.8. Dental caries
    • 2.2.9. Recurrent Bacterial Vaginosis and Urinary Tract Infection
    • 2.2.10. Skin Diseases
    • 2.2.11. Hyperoxaluria
    • 2.2.12. Urea Cycle Disorder
    • 2.2.13. Celiac Disease
    • 2.2.14. Non-alcoholic Steatohepatitis (NASH)
    • 2.2.15. Hepatic Encephalopathy
  • 2.3. Types of Microbiome therapeutics
    • 2.3.1. Prebiotics
    • 2.3.2. Live BioTherapeutic Agents (Probiotics)
    • 2.3.3. Fecal Microbiota Transplantation (FMT)
    • 2.3.4. Small Molecules
  • 2.4. Advances in Microbiome Research
    • 2.4.1. MetaHIT Consortium
    • 2.4.2. Human Microbiome Project
    • 2.4.3. Functional Metagenomics
    • 2.4.4. Microbiome Metabolomics
    • 2.4.5. Identifying Microbiome Targets-Enterome EB8018 Case Study
  • 2.5. Geographical Variation of Microbiome Composition

Chapter 3: Human Therapeutic and Diagnostic Pipeline Analysis

  • 3.0. Synopsis
  • 3.1. Clostridium Difficile
    • 3.1.1. SER-109 Seres Therapeutics
    • 3.1.2. SER-262 Seres Therapeutics
    • 3.1.3. RBX2660 Rebiotix
    • 3.1.4. VE303 Vedanta Biosciences
    • 3.1.5. IMM-529 Immuron
    • 3.1.6. MET-2 NuBiyota
    • 3.1.7. CP101 Finch Therapeutics
    • 3.1.8. ABI-M101 Assembly Biosciences
    • 3.1.9. CBM-588 Osel
    • 3.1.10. SYN-004 Synthetic Biologics
    • 3.1.11. SYN-006 Synthetic Biologics
  • 3.2. Ulcerative Colitis
    • 3.2.1. FIN-524 Finch Therapeutics
    • 3.2.2. SER-287 Seres Therapeutics
    • 3.2.3. ABI-M201 Assembly Biosciences
  • 3.3 Crohn's Disease
    • 3.3.1. ABI-M301 Assembly Biosciences
    • 3.3.2. Thetanix 4D Pharma
  • 3.4. Inflammatory Bowel Disease
    • 3.4.1. SER-301 Seres Therapeutics
    • 3.4.2. SGM-1019 Second Genome
    • 3.4.3. Blautix 4D Pharma
    • 3.4.4. SG-2-0776 Second Genome
    • 3.4.5. IBD110-Enterome/AbbVie
  • 3.5. Immuno-Oncology
    • 3.5.1. SER-401 Seres Therapeutics
    • 3.5.2. Colon Polyp & Colon Cancer Test - Metabiomics
    • 3.5.3. Colorectal Cancer (CRC) Test-Origin Sciences
  • 3.6. Graft Versus Host Disease
    • 3.6.1. SER-155 Seres Therapeutics
  • 3.7. Urinary Tract Infections
    • 3.7.1. LACTIN-V Osel
  • 3.8. Liver Disease
    • 3.8.1. SGM-1019 Second Genome
  • 3.9. Phenylketoneuria
    • 3.9.1. SYNB1020 Synlogic
    • 3.9.2. SYNB1618 Synlogic

Chapter 4: Market Analysis & Forecast to 2023

  • 4.0. Synopsis
  • 4.1. Market Applications
    • 4.1.1. Clostridium Difficile Infection
    • 4.1.2. Inflammatory Bowel Disease
    • 4.1.3. Ulcerative Colitis
    • 4.1.4. Crohn's Disease
    • 4.1.5. Liver Disease
    • 4.1.6. Immuno-Oncology
    • 4.1.7. Phenylketonuria
  • 4.2. Competitive Landscape
  • 4.3. Market Forecast to 2023
    • 4.3.1. Synopsis
    • 4.3.2. Primary Research, Clinical Trial and Pipeline Trends and Analysis
    • 4.3.3. Revenue Generation from Global Therapeutic and Diagnostic Microbiome Market 2018-2023
    • 4.3.4. Geographical Breakdown Analysis and Forecast to 2023
  • 4.3.5. Therapeutic and Diagnostic Submarket Breakdown By Indication

Chapter 5: Market Drivers, Trends & SWOT Analysis

  • 5.1. Market Drivers & Trends
  • 5.2. Market Threats & Challenges
  • 5.3. Market Opportunities

Chapter 6: Investment and Market Deals

  • 6.1. Public and Private Funding in the Microbiome Space
  • 6.2. Current Market Deals

Chapter 7: Venture Capital and The Microbiome

  • 7.0. Synopsis
  • 7.1. How Much Investment Has been Poured into the Microbiome Space in Recent Years?
  • 7.2. What Investment Firms are Interested in the Microbiome Space?
  • 7.3. What Companies are Receiving Funding?
  • 7.4. What Funding Cycles are Emerging in this Space?

Chapter 8: Major Players and Company Profiles

  • 8.1. 4D Pharma
  • 8.2. Abbvie
  • 8.3. Allergan
  • 8.4. Assembly Biosciences
  • 8.5. Bristol Myers Squibb
  • 8.6. C3J Therapeutics
  • 8.7. Da Volterra
  • 8.8. Enterome
  • 8.9. Finch Therapeutics
  • 8.10. Immuron
  • 8.11. Matrisys Bioscience
  • 8.12. Merck
  • 8.13. Osel
  • 8.14. Pfizer
  • 8.15. Quorum Innovations
  • 8.16. Rebiotix
  • 8.17. Second Genome
  • 8.18. Seres Therapeutics
  • 8.19. Synlogic
  • 8.20. Synthetic Biologics
  • 8.21. Takeda
  • 8.22. Vedanta Biosciences

List of Exhibits

  • Exhibit 2.1: Microbiota Associated with Cancer Development
  • Exhibit 2.2: Gut Microbiota Dysbiosis and the Development of Inflammatory Immune Responses
  • Exhibit 2.3: Microbiota Metabolites
  • Exhibit 2.4: Association of Diet and Microbiota with Development of Diabetes
  • Exhibit 2.5: Dysbiotic Microbiota and Development of the Inflammatory Response Following C. difficile Infection
  • Exhibit 2.6: Host-Microbe Interactions During the Pathogenesis of Dental Caries
  • Exhibit 2.7: Brain Dysfunction Due to Altered Microbiota in Cirrhosis
  • Exhibit 2.8: Therapeutic Intervention Strategies for Microbiome Dysbiosis
  • Exhibit 2.9: Characteristics of Prebiotics and Probiotics
  • Exhibit 2.10: Probiotic Safety, Functional and Technological Usability Requirements
  • Exhibit 2.11: Probiotics Action within the Human Gut
  • Exhibit 2.12: Clinical Trials Investigating Probiotics and Obesity
  • Exhibit 2.13: Clinical Trials on Probiotics, Type 2 Diabetes & Non-Alcoholic Fatty Liver Disease
  • Exhibit 2.14: Clinical Trials Investigating Probiotics and Irritable Bowel Syndrome
  • Exhibit 2.15: Timeline of Fecal Microbiota Transplantation
  • Exhibit 2.16: Small Molecules Derived from the Human Microbiota
  • Exhibit 2.17: Gut IBD Microbiome Analysis by the Human Microbiome Project
  • Exhibit 2.18: Prediabetes Microbiome Analysis by the Human Microbiome Project
  • Exhibit 2.19: Pregnancy and Neonate Microbiome Analysis by the Human Microbiome Project
  • Exhibit 2.20: Metagenomic Analysis of the Gut Microbiome
  • Exhibit 2.21: Microbiome Metabolomic Applications in Health and Disease
  • Exhibit 2.22: Metabolites Associated with Microbial and Host metabolism
  • Exhibit 2.23: Enterome Platform to Study Gut Microbiome in IBD
  • Exhibit 2.24: Enterome EB8018 Anti-FimH Molecule for the Treatment of IBD
  • Exhibit 2.25: Global Microbiome Diversity by Geography and Body Area
  • Exhibit 3.1: Human Therapeutics Microbiome Product Pipeline
  • Exhibit 3.2: Number of Human Therapeutic and Diagnostic Microbiome Pipeline Products, Globally
  • Exhibit 3.3: Human Microbiome Therapeutics Pipeline by Drug, Company, Development Stage and Indication
  • Exhibit 3.4: IMM-529 by Immuron Mechanism of Action
  • Exhibit 4.1: Microbiome Therapeutics in Clostridium Difficile Infection
  • Exhibit 4.2.: Microbiome Therapeutic and Diagnostic Major Player Market Share Forecast 2023
  • Exhibit 4.3: Percentage of PubMed Citations by Microbiome Disease Application
  • Exhibit 4.4: Percentage of Clinical Trials by Microbiome Disease Application
  • Exhibit 4.5: Global Therapeutic and Diagnostic Microbiome Market Revenue Forecast 2018-2023
  • Exhibit 4.6: Current Global Therapeutic and Diagnostic Market Share of Microbiome Market
  • Exhibit 4.7: Global Therapeutic Microbiome Market Revenue Forecast 2018-2023
  • Exhibit 4.8: Global Diagnostic Microbiome Market Revenue Forecast 2018-2023
  • Exhibit 4.9: Geographical Microbiome Market Analysis 2018
  • Exhibit 4.10: Geographical Microbiome Market Forecast 2023
  • Exhibit 4.11: Gastrointestinal Microbiome Therapeutic Market Forecast to 2023
  • Exhibit 4.12: Metabolic Microbiome Therapeutic Market Forecast to 2023
  • Exhibit 4.13: Cancer Microbiome Therapeutic Market Forecast to 2023
  • Exhibit 4.14: Neurological Microbiome Therapeutic Market Forecast to 2023
  • Exhibit 4.15: Autoimmune Microbiome Therapeutic Market Forecast to 2023
  • Exhibit 4.16: Skin Microbiome Therapeutic Market Forecast to 2023
  • Exhibit 4.17: Gastrointestinal Microbiome Diagnostic Market Forecast to 2023
  • Exhibit 4.18: Metabolic Microbiome Diagnostic Market Forecast to 2023
  • Exhibit 4.19: Cancer Microbiome Diagnostic Market Forecast to 2023
  • Exhibit 4.20: Neurological Microbiome Diagnostic Market Forecast to 2023
  • Exhibit 4.21: Autoimmune Microbiome Diagnostic Market Forecast to 2023
  • Exhibit 4.22: Skin Disorders Microbiome Diagnostic Market Forecast to 2023
  • Exhibit 5.1: Drivers of the Microbiome Market
  • Exhibit 5.2: Threats and Challenges of the Microbiome Market
  • Exhibit 6.1: Current Market Deals in the Microbiome Space
  • Exhibit 7.1: Total Venture Capital Invested in the Microbiome Space, 2013-2017
  • Exhibit 7.2: Venture Capital Invested in the Microbiome Space by Therapeutics, Diagnostics, Agriculture and Consumer Products, 2013-2017
  • Exhibit 7.3: Major Investment Firms and Investment Numbers in the Microbiome Industry by Therapeutics, Diagnostics, Agriculture and Consumer Products, 2010-2017
  • Exhibit 7.4: Major Microbiome Companies and Investment Received to 2017
  • Exhibit 7.5: Microbiome Industry Investors and Companies
  • Exhibit 7.6: Major Microbiome Companies and Investment Received to 2017
  • Exhibit 7.7: Therapeutic and Diagnostic Microbiome Investments by Funding Cycle 2010-2017
  • Exhibit 8.1: 4D Pharma Development Pipeline Product Portfolio
  • Exhibit 8.2: Assembly Biosciences Pipeline Product Pipeline
  • Exhibit 8.3: Assembly BioSciences R&D Expenditure 2015-2017
  • Exhibit 8.4: C3J Therapeutics STAMP Platform
  • Exhibit 8.5: C3J Therapeutics Product Pipeline
  • Exhibit 8.6: Da Volterra Product Pipeline Portfolio
  • Exhibit 8.7: Enterome Drug Discovery Platform
  • Exhibit 8.8: Enterome Product Pipeline
  • Exhibit 8.9: Osel Pipeline Product Portfolio by Clinical Stage
  • Exhibit 8.10: Quorum Innovations Product Pipeline Portfolio
  • Exhibit 8.11: Microbiota Restoration Therapy Application Areas
  • Exhibit 8.12: Second Genome Product Pipeline Portfolio
  • Exhibit 8.13: Seres Therapeutics Product Pipeline
  • Exhibit 8.14: Seres Therapeutics R&D Expenditure 2015-2017
  • Exhibit 8.15: Synlogic Product Pipeline Portfolio
  • Exhibit 8.16: Synthetic Biologics Product Pipeline
  • Exhibit 8.17: Synthetic Biologics R&D Expenditure 2015-2017
Back to Top
아시아 최대 시장정보 제공
전세계에서 발행되고 있는 모든 시장조사보고서를
다루고 있습니다.
사이트에서 검색되지 않는 보고서도 문의 바랍니다.
 
BCC Research